Strata Critical Medical, Inc. SRTA
5.33
0.06
1.14%
as of 25 Sep
- Market cap
- $476.8M
- P/E
- 10.5×
Follow SRTA
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
10.33 | 9.49 | 7.24 | 10.39 |
P/S ratio |
3.43 | 2.00 | 1.56 | 1.78 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(11.19) | (47.53) | 91.80 | 79.89 | |
P/B ratio |
1.47 | 1.41 | 1.25 | 1.63 | |
Price to Tangible BV |
2.81 | 2.75 | 2.36 | 4.04 | |
EV/Sales |
2.80 | 1.69 | 1.30 | 1.69 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(8.05) | (6.82) | (6.65) | (11.97) | |
EV/FCF |
(6.05) | (5.56) | (5.12) | (8.71) | |
Quick Ratio |
4.08 | 5.13 | 4.71 | 1.45 | |
Current Ratio |
4.39 | 6.38 | 5.93 | 2.64 | |
Net Debt/EBITDA |
19.44 | 18.10 | (686.66) | (7.41) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.39 | 0.68 | 0.79 | 0.87 | |
Operating CF/Net income |
(0.65) | 0.94 | 1.80 | (0.54) | |
Capex/Depreciation |
(1.87) | (0.67) | (1.79) | (0.33) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.92% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
34.04% | 27.66% | 23.16% | 19.30% | |
Intangible Assets out of Total Assets |
0.40 | 0.42 | 0.41 | 0.50 | |
Share Based Compensation of Revenue |
3.41% | 9.86% | 7.47% | 5.11% | |
Graham Net Nets |
0.17 | 0.20 | 0.23 | 0.15 | |
Graham Number |
6.15 | 6.23 | 6.59 | 6.08 | |
Earnings Yield |
9.68% | 10.54% | 13.81% | 9.62% | |
Free Cash Flow Yield |
(13.52%) | (15.18%) | (16.30%) | (10.90%) | |
Revenue per Share |
0.60 | 0.81 | 0.79 | 0.84 | |
Operating CF per Share |
(0.45) | (0.10) | 0.05 | 0.07 | |
Capex per Share |
(0.04) | (0.02) | (0.06) | (0.03) | |
Free Cash Flow per Share |
(0.49) | (0.13) | (0.02) | 0.03 | |
Cash per Share |
0.92 | 0.75 | 0.69 | 0.27 | |
Shareholders Equity per Share |
3.43 | 3.40 | 3.35 | 3.24 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.43 | 3.40 | 3.35 | 3.24 | |
Free Cash Flow |
(40.49) | (10.31) | (1.60) | 2.88 | |
Working Capital |
94.61 | 106.40 | 103.20 | 75.23 | |
Capital Expenditures |
(3.19) | (2.00) | (5.48) | (2.80) | |
Net Current Asset Value |
70.40 | 79.79 | 82.26 | 67.63 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.06 | 0.03 | 0.08 | 0.04 | |
Net Profit Margin |
116.47% | (13.23%) | 3.20% | (14.50%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
31.01 | 29.89 | 30.87 | 35.79 | |
Average Payables |
21.62 | 14.18 | 15.23 | 16.03 | |
Average Assets |
309.01 | 291.07 | 289.08 | 295.31 | |
Average Common Equity |
258.25 | 250.51 | 252.73 | 251.21 |
Columns are period end dates